For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Four Pharmas Launch Filgrastim, Third Biosimilars in Japan
June 3, 2013
- EvaluatePharma Estimates Orphan Drug Market Will Grow to US$127 Billion by 2018
May 31, 2013
- Kyowa Kirin Launches Parkinson’s Disease Treatment Nouriast in Japan
May 31, 2013
- Sawai Aims for All Its New MRs to Pass MR Examination for Fifth Year in a Row
May 31, 2013
- Astellas, Amgen Clinch Strategic Alliance on 5 Products; JV to Begin Operations in October
May 30, 2013
- Eisai Launches Antiepileptic Treatment Inovelon
May 30, 2013
- Nippon Shinyaku Launches Regtect for Supporting Maintenance of Abstinence in Alcohol-Dependent Patients
May 30, 2013
- Ex-Novartis Employee Attended Key Panel Meetings for Diovan Trial
May 29, 2013
- MTPC Files NDA for SGLT-2 Inhibitor Canagliflozin in Japan
May 29, 2013
- Sales of 27 JPMA Member Companies Up 2.6%, First Rise in Two Years Thanks to Overseas Sales Growth
May 28, 2013
- Kyorin Aims for Pentasa Sales Increase in FY2013 with Suppository Formulation: President Yamashita
May 28, 2013
- NPhA Member Companies Will Strive to Reach Price Agreements with Wholesalers by September: Chairman Nakamura
May 28, 2013
- Hisamitsu, Asahi Kasei to Launch Overactive Bladder Treatment Neoxy Tape in June
May 28, 2013
- Astellas Files NDA for Prostate Cancer Treatment Enzalutamide in Japan
May 28, 2013
- “No Indication” of Data Manipulation in Diovan Studies: Novartis
May 27, 2013
- Bayer Launches Anticancer Treatment Stivarga
May 27, 2013
- 2012 Earnings: Foreign Pharmas’ Japan Units Underperform Market Growth, Operating Profit Down 21%
May 27, 2013
- Kyowa Kirin to Launch DPP-4 Inhibitor Onglyza in July Without Concurrent Use Restrictions
May 27, 2013
- OPF to Exclusively Market 3 Plasma Volume Expanders in Japan
May 24, 2013
- Daiichi Sankyo: Ranbaxy Former Shareholders Hid Critical Information
May 24, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…